Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 3/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | TDO2 | P48775 | 2/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | HRH2 | P25021 | 2/20 | 0.31 |
| ▸ | HRH1 | P35367 | 2/20 | 0.31 |
| ▸ | KRAS | P01116 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
| ▸ | ITGAV | P06756 | 1/20 | 0.30 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30869053 | 0.89 | ATR (0.34) | ATRRXRARXRBRXRG | |
| SCHEMBL30797730 | 0.89 | ATR (0.44) | ATRIDO1TDO2RXRARXRB | |
| SCHEMBL30869099 | 0.88 | ATR (0.36) | ATRRXRARXRBRXRGKRAS | |
| SCHEMBL30869047 | 0.87 | ATR (0.33) | ATRAAK1RXRARXRBRXRG | |
| SCHEMBL30869072 | 0.86 | ATR (0.34) | ATRRXRARXRBRXRG | |
| SCHEMBL27378131 | 0.80 | RXRA (0.39) | ATRIDO1TDO2AAK1RXRA | |
| SCHEMBL30797598 | 0.80 | RXRA (0.39) | ATRIDO1TDO2AAK1RXRA | |
| SCHEMBL30797740 | 0.79 | ATR (0.43) | ATRIDO1TDO2RXRARXRB | |
| SCHEMBL30869074 | 0.79 | ATR (0.43) | ATRTDO2RXRARXRBRXRG | |
| SCHEMBL30869065 | 0.78 | ATR (0.42) | ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085062-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTPR LTD (GB) | 2026-03-26 | — | — | US | disclosed |
| EP-4584249-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024052702-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085062-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CSNK1A1, CSNK1G1, CSNK2A3 | ATR 984/4885IDO1 1378/4885TDO2 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.